Eva Rosell Solano

Women TechEU Chapter meetups! 📍On 4 March, Women TechEU held its first Barcelona Chapter meetup during Mobile World Congress week. Organised by AFAEMME and EIT Health Spain , the event brought together winners and partners for an informal networking evening. 🌟Highlights included presentations from our inspiring winners: Pilar Domingo-Calap (Evolving Therapeutics): tackling multidrug-resistant bacteria with innovative solutions to prevent infections and reduce antibiotic dependence. Dani Tost and Núria Bonet Rimbau (Virmedex): revolutionising healthcare training through AI, VR, and simulation for complex medical techniques. Aya Elzoheery (Futurity Systems): creating AI-powered strategic planning tools to anticipate and tackle future challenges with clarity. Yonca Belce, PhD (CellFlow): developing advanced bio-regenerative cell therapies through cutting-edge biotechnology. Find out more about the winners on the DataHub:  https://lnkd.in/d-9SM999 EBAN - European Business Angel Network Sploro #WomenTechEU #WomenEntrepreneurs #WomenInBusiness #deeptech #FundedbytheEU

52

1 comentario

Spain – Generic Pharmaceutical Retail Market (2025)   1. Market Size & Growth Total pharmaceutical market (2023): ~€22.4B Generics account for ~47% of prescription volume, ~23–25% of value No officially segmented 2025 generics value available; IQVIA confirms slightly positive growth trend CAGR (2025–2029): ~2–3% based on regulatory stability and aging population   2. Market Structure Retail market includes 22,000+ community pharmacies, all privately owned under regulation No chains allowed; pharmacies are individually licensed Dominant local and EU-based generics: Cinfa, Kern Pharma, Sandoz, Teva Spain   3. eCommerce Segment Online sales of OTC drugs permitted through certified pharmacies Rx sales online are prohibited Top ePharmacy platforms: Promofarma, Dosfarma, Mifarma   4. OTC Segment Estimated OTC segment (2025): ~€3.2B Generics dominate pain, flu, GI, and dermatology OTC categories   5. Market Dynamics Mandatory substitution with lowest-cost generic in reimbursed categories High public system coverage (SNS); co-pays encourage generic uptake Reference pricing system (PRS) enforces price caps and promotes equivalence   6. Consumer Behaviour Rising trust in generics among all age groups Pharmacists play a strong role in guiding substitution Online buying focused on OTC wellness and supplements   7. Key Drivers Aging population (over 20% aged 65+) National health system pressures to reduce drug bill Chronic disease prevalence (diabetes, cardiovascular, depression)   8. Key Challenges Regulatory complexity across autonomous communities Strict ePharmacy limitations hinder Rx digital expansion Price compression under reference pricing squeezes retail margins 9. Opportunities Expansion of private-label generics Chronic condition OTC bundles sold via ePharmacy platforms Digital tools for adherence + pharmacist consultation 10. Regulatory Environment Regulated by: AEMPS (Spanish Agency of Medicines) MSCBS (Ministry of Health) Generics mandatory for SNS reimbursement unless prescriber blocks OTC eCommerce allowed under EU and national pharmacy regulations 11. Strategic Considerations Position generics within reference price groups for inclusion in reimbursement Partner with large online OTC pharmacy platforms Align with EU GMP and pharmacovigilance standards

25

1 comentario

🔬 Research and innovation are key to the future of medicine. We are proud to support startups with strong scientific and technological potential, such as Amadix - a Spanish company that has developed an innovative technology to detect cancer through a simple blood test, even before the first symptoms appear. In February, we provided Amadix with a €15 million loan to support: ✔️Research and development of its product portfolio, including PreveCol, its flagship colorectal cancer screening test, as well as PancreaDix and DiagnoLung for pancreatic and lung cancer detection ✔️Clinical validation of PreveCol in the United States ✔️The company’s international expansion, strengthening its presence across Europe and North America. 🗨️ “It is very encouraging to see organisations like the EIB supporting companies like ours, contributing to Europe's Beating Cancer Plan and driving our international growth”, says Rocio Arroyo, Amadix’s founder and CEO. “Thanks to the EIB’s support, more people will have access to innovative solutions such as liquid biopsy to prevent cancer, a leading cause of death worldwide, to live longer and better.” Discover the story of this pioneering company 🎥⤵️

138

4 comentarios

EGPA is a rare disease affecting lungs, heart, skin, and nerves. Early diagnosis is crucial, yet it can take up to 9 years due to its complexity. This September, start-ups will pitch their innovative solutions at the EIT Health Open Innovation Challenge in collaboration with GSK Spain and Hospital Universitario La Paz These solutions aim to improve early detection, monitoring, and patient outcomes for EGPA. Stay tuned to discover how innovators are shaping the future of rare disease care! 🚀 #EITHealth #OpenInnovation #EGPA #Diagnostics #HealthInnovation

43

1 comentario